Using microRNA-based nanoparticles to treat multiple myeloma
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy
['FUNDING_R01'] · DANA-FARBER CANCER INST · NIH-11060969
This study is exploring a new way to treat advanced multiple myeloma using tiny particles that deliver special molecules directly to cancer cells, which could help patients who haven't had success with standard treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11060969 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative therapies for multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. The approach involves using microRNA-based polymeric nanoparticles to target and deliver treatment directly to cancer cells, overcoming challenges like drug resistance and immune evasion. By modifying the delivery methods of microRNAs, the research aims to enhance their stability and effectiveness in combating advanced stages of the disease. Patients with advanced multiple myeloma who have not responded to conventional treatments may particularly benefit from this targeted therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced multiple myeloma who have become resistant to standard therapies.
Not a fit: Patients with early-stage multiple myeloma or those who have not yet undergone treatment may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced multiple myeloma, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using microRNA therapies for cancer treatment, indicating that this approach could be a viable and innovative strategy.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CARRASCO, RUBEN D — DANA-FARBER CANCER INST
- Study coordinator: CARRASCO, RUBEN D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced disease, anti-cancer therapy